Authors


the 2Veterans Administration

Latest:

Are HDL cholesterol levels clinically significant in patients with low LDL cholesterol levels?

There is some debate about whether the risk of cardiovascular events associated with low high-density lipoprotein (HDL) cholesterol levels is attenuated by very low low-density lipoprotein (LDL) cholesterol levels (< 60 mg/dL), which can be obtained with statins and combination therapy.





Eric R. Bates, MD

Latest:

PCI Versus CABG in Patients with Left Main CAD

Choosing the revascularization strategy is a complex decision for the Heart Team and patient.






Tejas Alexander, MD

Latest:

Undiagnosed diabetes mellitus in coronary artery bypass graft surgery

We examined the prevalence and risks associated with undiagnosed diabetes mellitus among more than 7000 patients who had undergone coronary artery bypass graft surgery. At the perioperative and postoperative stages, patients with undiagnosed diabetes showed a significantly higher morbidity and mortality rate.



James Swinarski

Latest:

Apple is Actively Recruiting Healthcare Providers at their Retail Stores

Apple recently held a workshop designed for healthcare professionals to learn more about medical apps, how to use them, and where to get them.


Tassy Hayden, MD

Latest:

Adding Topiramate to the Obesity Treatment Toolbox

As the prevalence of overweight and obese patients continues to surge, an efficacious pharmacological treatment for obesity is desperately needed in everyday clinical practice.




Rehan Qayyum, MD

Latest:

Non–ST-segment elevation ACS: Should all patients undergo cardiac catheterization?

We performed a systematic review and meta-analysis of all clinical trials comparing routine invasive strategy with selective invasive strategy in patients with non–ST-segment elevation acute coronary syndrome. We did not find either strategy to offer an advantage over the other, even when we excluded trials that did not use coronary stents and glycoprotein IIb/IIIa inhibitors.




Liam Jette, MS IV

Latest:

Does Sodium Restriction Improve Cardiovascular Outcomes?

Dietary sodium restriction is frequently recommended as a means to manage hypertension, congestive heart failure and cardiovascular disease. However, with the growing focus on patient-centered outcomes rather than disease-centered outcomes, the importance of sodium restriction becomes less clear.




Trevor J. Orchard, MD

Latest:

Effectiveness and Cost-Effectiveness of Diabetes Prevention among Adherent Participants

Over 10 years, lifestyle intervention and metformin were cost-effective or cost saving compared with placebo.



Glenn N. Levine, MD, FAHA, FACC

Latest:

Novel Treatment for Refractory Angina Using a Coronary Sinus Reducer Device: A Glimmer of Hope

Refractory angina is a loosely defined term generally referring to the persistence of life-impacting angina despite maximal antianginal medications and, when possible, coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]). Numerous novel pharmacotherapies and mechanical interventions have been proposed, and studies conducted, to treat patients with refractory angina.


Debabrata Mukherjee, MD, MS, FACC Editor-in-Chief

Latest:

Knocking on Winter's Door

In this issue of Cardiology Review, we cover a wide variety of topics while saying hello to the winter of 2014.


Bill Schu

Latest:

Presidential Candidates on Health Care Issues: Bernie Sanders

Part of an ongoing series that takes a high-level look at the positions of the leading nominees for President when it comes to political issues potentially impacting physicians, this installment focuses on Bernie Sanders.




Cynthia L. Bero, MPH

Latest:

Achieving Meaningful Use: A Health System Perspective

The experience of Partners HealthCare offers some unique insights into the process of electronic medical record adoption across a large, diverse health system.


Steven B. Shoemaker, MD

Latest:

High clopidogrel maintenance dosage in patients with diabetes mellitus and coronary artery disease

Patients with type 2 diabetes mellitus have decreased platelet inhibition and decreased responsiveness to standard doses of clopidogrel compared with patients without diabetes. In this pilot study, we showed that increasing the maintenance dose of clopidogrel to 150 mg leads to enhanced platelet inhibition compared with the standard dose of 75 mg in patients with type 2 diabetes with suboptimal responsiveness. The clinical implications of these findings are unknown, however, and need to be evaluated in large-scale clinical trials.

© 2024 MJH Life Sciences

All rights reserved.